{ "items" : [
    { "id" : "http://dbpedia.org/resource/Adalimumab"
      "properties" : {
        "http://www.w3.org/2000/01/rdf-schema#comment" : [ "Adalimumab, trade names Humira (\"human monoclonal antibody in rheumatoid arthritis\") and Exemptia are TNF inhibiting anti-inflammatory drug manufactured by AbbVie and Zydus Cadila respectively. Adalimumab binds to tumor necrosis factor-alpha (TNFα). TNFα normally binds to TNFα receptors, which leads to the inflammatory response of autoimmune diseases. By binding to TNFα, adalimumab reduces this inflammatory response." ] ,
        "http://xmlns.com/foaf/0.1/depiction" : [ "http://commons.wikimedia.org/wiki/Special:FilePath/Adalimumab_structure.png" ] ,
        "http://dbpedia.org/ontology/atcPrefix" : [ "L04" ] ,
        "http://dbpedia.org/ontology/atcSuffix" : [ "AB04" ] ,
        "http://dbpedia.org/ontology/bioavailability" : [ 64 ] ,
        "http://dbpedia.org/ontology/casNumber" : [ "331731-18-1" ] ,
        "http://dbpedia.org/ontology/drugbank" : [ "DB00051" ] ,
        "http://dbpedia.org/ontology/fdaUniiCode" : [ "FYS6T7F842" ] ,
        "http://dbpedia.org/ontology/thumbnail" : [ "http://commons.wikimedia.org/wiki/Special:FilePath/Adalimumab_structure.png?width=300"] } } }
